Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

Cited by (1,019)

Items 601–700 of 1,019

1. Effects of LDL Receptor Modulation on Lymphatic Function
   Andreea Milasan, François Dallaire, Gaétan Mayer, Catherine Martel · 2016 · Scientific Reports
2. Quantitative proteomic analysis of milk fat globule membrane (MFGM) proteins from donkey colostrum and mature milk
   Weixuan Li, Mohan Li, Xueyan Cao, Mei Yang, Hongjiao Han, Fanhua Kong, Xiqing Yue · 2019 · Food & Function
3. Deepening our understanding of HDL proteome
   Graziella E. Ronsein, Tomáš Vaisar · 2019 · Expert Review of Proteomics
4. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment
   Anusha Sunkara, Albert E. Raizner · 2019 · Methodist DeBakey Cardiovascular Journal
5. Rosuvastatin calcium-based novel nanocubic vesicles capped with silver nanoparticles-loaded hydrogel for wound healing management: optimization employing Box–Behnken design:in vitroandin vivoassessment
   Heba Farouk Salem, Mohamed Mahmoud Nafady, Mohamed G. Ewees, Hend M Hassan, Rasha A. Khallaf · 2020 · Journal of Liposome Research
6. Triglyceride-Glucose Index Predicts Future Atherosclerotic Cardiovascular Diseases: A 16-Year Follow-up in a Prospective, Community-Dwelling Cohort Study
   Joon Ho Moon, Yongkang Kim, Tae Jung Oh, Jae Hoon Moon, Soo Heon Kwak, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi, Nam H. Cho · 2023 · Endocrinology and Metabolism
7. Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
   Susan Kühnast, Marta F. Fiocco, José W.A. van der Hoorn, Hans M. G. Princen, J. Wouter Jukema · 2015 · European Journal of Pharmacology
8. Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia
   Amit V. Khera, Arman Qamar, Muredach P. Reilly, Richard L. Dunbar, Daniel James Rader · 2014 · The American Journal of Cardiology
9. Role of HDL in Those with Diabetes
   Carlos G. Santos‐Gallego, Robert S. Rosenson · 2014 · Current Cardiology Reports
10. Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA])
    David M. Tehrani, Yanglu Zhao, Michael Joseph Blaha, Samia Mora, Rachel H. Mackey, Erin D. Michos, Matthew Jay Budoff, William C. Cromwell, James D. Otvos, Paul D. Rosenblit et al. · 2016 · The American Journal of Cardiology
11. Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs
    Teresa Padró, Judit Cubedo, Sandra Camino-López, Maria Teresa Béjar, Soumaya Ben‐Aicha, Guiomar Mendieta, Joan Carles Escolá‐Gil, Rafael Escate, Manuel Gutiérrez, Laura Casaní et al. · 2017 · Journal of the American College of Cardiology
12. High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization
    Gilles Montalescot, Grégoire Rangé, Johanne Silvain, Jean‐Louis Bonnet, Ziad Boueri, Olivier Barthélémy, Guillaume Cayla, Loïc Belle, Eric VAN BELLE, Thomas Cuisset et al. · 2014 · Circulation
13. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis
    Panteleimon Pantelidis, Evangelos K. Oikonomou, Stamatios Lampsas, George Ε. Zakynthinos, Antonios Lysandrou, Konstantinos I. Kalogeras, Efstratios Katsianos, Panagiotis Theofilis, Gerasimos Siasos, Michael Vavuranakis et al. · 2023 · Cardiovascular Research
14. Remnant cholesterol and ischemic heart disease
    Anette Varbo, Børge Grønne Nordestgaard · 2014 · Current Opinion in Lipidology
15. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future
    Christian Weber, Lina Badimón, François Mach, Emiel P. C. van der Vorst · 2017 · Thrombosis and Haemostasis
16. Targeting Non-coding RNA in Vascular Biology and Disease
    John Hung, Vladislav Miscianinov, Judith C. Sluimer, David Ernest Newby, Andrew Howard Baker · 2018 · Frontiers in Physiology
17. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen
    Rocha, Natalia A., East, Cara, Zhang, Jun, McCullough, Peter A. · 2017 · Current Atherosclerosis Reports
18. Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes
    Maryam Khavandi, Francisco Duarte, Henry N. Ginsberg, Gissette Reyes‐Soffer · 2017 · Current Cardiology Reports
19. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary
    Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel E. Dagogo-Jack, Michael Davidson, DANIEL F. EINHORN, Jeffrey R. Garber et al. · 2015 · Endocrine Practice
20. Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets
    L. Masana, Daiana Ibarretxe, Núria Plana · 2020 · Current Cardiology Reports
21. Nicotinic acid as a lipid-modifying drug – A review
    Ulrich Julius, Sabine Fischer · 2013 · Atherosclerosis Supplements
22. Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes.
    N. John Bosomworth · 2013 · Europe PMC (PubMed Central)
23. Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus
    Esther M. M. Ooi, Gerald Francis Watts, Dick C. Chan, Jing Pang, Vijay S. Tenneti, Sandra J. Hamilton, Sally P.A. McCormick, Santica M. Marcovina, P. Hugh R. Barrett · 2015 · Arteriosclerosis Thrombosis and Vascular Biology
24. Combined dyslipidemia in childhood
    Rae-Ellen Webb Kavey · 2015 · Journal of clinical lipidology
25. Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women
    Michelle Schmiegelow, Haley Hedlin, Marcia L. Stefanick, Rachel H. Mackey, Matthew Allison, Lisa Warsinger Martin, Jennifer G. Robinson, Mark Andrew Hlatky · 2015 · Circulation Cardiovascular Quality and Outcomes
26. Does Vascular Calcification Accelerate Inflammation?
    Francis Richard Joshi, Nikil K Rajani, Markus Abt, Mark Woodward, Jan A. Bucerius, Venkatesh Mani, Ahmed A Tawakol, David G. Kallend, Zahi Adel Fayad, James H F Rudd · 2016 · Journal of the American College of Cardiology
27. Future perspectives of the pharmacological management of diabetic dyslipidemia
    Angelo Maria Patti, Rosaria Vincenza Giglio, Νικόλαος Παπάνας, Manfredi Rizzo, Ali Abbas Rizvi · 2019 · Expert Review of Clinical Pharmacology
28. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia
    Zonglei Zhao, Song Du, Shuxin Shen, Ping Luo, Shoukun Ding, Guanggong Wang, Lixia Wang · 2019 · Medicine
29. High-Density Lipoprotein Cholesterol and All-Cause and Cause-Specific Mortality Among the Elderly
    Zhihao Li, Yuebin Lv, Wen-Fang Zhong, Xiang Gao, Virginia B. Kraus, Mengchen Zou, Xi-Ru Zhang, Fu-Rong Li, Jin-Qiu Yuan, Xiao‐Ming Shi et al. · 2019 · The Journal of Clinical Endocrinology & Metabolism
30. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease
    Kevin O’Fee, Elena Deych, Oriana Ciani, David Brown · 2021 · JAMA Internal Medicine
31. Target Populations for Novel Triglyceride-Lowering Therapies
    Nordestgaard, Ask T., Tybjærg-Hansen, Anne, Mansbach, Hank, Kersten, Sander, Nordestgaard, Børge G., Rosenson, Robert S. · 2025 · Journal of the American College of Cardiology
32. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study
    Andrews, Jordan, Janssan, Alex, Nguyen, Tracy, Pisaniello, Anthony D., Scherer, Daniel J., Kastelein, John J. P., Merkely, Bela, Nissen, Steven E., Ray, Kausik, Schwartz, Gregory G. et al. · 2017 · Cardiovascular Diagnosis and Therapy
33. Effects of Diet on 10-Year Atherosclerotic Cardiovascular Disease Risk (from the DASH Trial)
    Sun Young Jeong, Christina C. Wee, Lara C. Kovell, Timothy B. Plante, Edgar R. Miller, Lawrence J. Appel, Kenneth Jay Mukamal, Stephen Paul Juraschek · 2022 · The American Journal of Cardiology
34. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies
    Ibrahim S. Alhomoud, Azita H. Talasaz, Anurag Mehta, Michael S. Kelly, Evan M. Sisson, John D. Bucheit, Roy Brown, Dave L. Dixon · 2023 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
35. Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein
    Valentina Kon, Haichun Yang, Sergio Fazio · 2015 · Archives of Medical Research
36. Human genetics of HDL: Insight into particle metabolism and function
    Liam R. Brunham, Michael R. Hayden · 2015 · Progress in Lipid Research
37. Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells
    Linhua Zhang, Vaijinath S. Kamanna, Shobha H. Ganji, Ximing Xiong, Moti L. Kashyap · 2012 · Journal of Lipid Research
38. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients
    Stephen James Nicholls, Giacomo Ruotolo, H Bryan Brewer, Ming-Dauh Wang, Liping Liu, Mark B. Willey, Mark A. Deeg, Kathryn A. Krueger, Steven E. Nissen · 2015 · Journal of clinical lipidology
39. A review of PCSK9 inhibition and its effects beyond LDL receptors
    Dixon, Dave L., Trankle, Cory, Buckley, Leo, Parod, Eric, Carbone, Salvatore, Van Tassell, Benjamin W., Abbate, Antonio · 2016 · Journal of Clinical Lipidology
40. Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?
    Baohai Shao, Jay W. Heinecke · 2017 · Expert Review of Proteomics
41. High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus
    Yi He, Vishal M Kothari, Karin Bornfeldt · 2018 · Arteriosclerosis Thrombosis and Vascular Biology
42. New Frontiers in Lp(a)-Targeted Therapies
    Matthew J. Borrelli, Amer Youssef, Michael B. Boffa, Marlys L. Koschinsky · 2019 · Trends in Pharmacological Sciences
43. High Density Lipoproteins and Diabetes
    Blake J. Cochran, Kwok Leung Ong, Bikash Manandhar, Kerry‐Anne Rye · 2021 · Cells
44. Lipoprotein(a)
    Florian Kronenberg · 2021 · Handbook of experimental pharmacology
45. LCAT- targeted therapies: Progress, failures and future
    Kaixu Yang, Junmin Wang, Hongjiao Xiang, Peilun Ding, Tao Wu, Guang Ji · 2022 · Biomedicine & Pharmacotherapy
46. Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review
    Cristina Madaudo, Giada Bono, Antonella Ortello, Giuseppe Astuti, Giulia Mingoia, Alfredo Ruggero Galassi, Vincenzo Sucato · 2024 · Journal of Personalized Medicine
47. Exercise-mediated changes in high-density lipoprotein: Impact on form and function
    Alisa D. Blazek, Jessica Rutsky, Kwame Osei, Andrei Maiseyeu, Sanjay Rajagopalan · 2013 · American Heart Journal
48. Combination therapy in dyslipidemia: Where are we now?
    Alberico Luigi Catapano, Michel Farnier, JoAnne Micale Foody, Peter Paul Toth, Joanne E. Tomassini, Philippe Brudi, Andrew M. Tershakovec · 2014 · Atherosclerosis
49. Clinical Factors Associated With High-Risk Carotid Plaque Features as Assessed by Magnetic Resonance Imaging in Patients With Established Vascular Disease (from the AIM-HIGH Study)
    Xue Qiao Zhao, Thomas S. Hatsukami, Daniel S. Hippe, Jie Sun, Niranjan Balu, Daniel A. Isquith, John R. Crouse, Todd J. Anderson, John Huston, Nayak Lincoln Polissar et al. · 2014 · The American Journal of Cardiology
50. Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments
    Janet E. Digby, Neil Ruparelia, Robin P. Choudhury · 2011 · Arteriosclerosis Thrombosis and Vascular Biology
51. High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis
    Alice Ossoli, Chiara Pavanello, Laura Calabresi · 2016 · Endocrinology and Metabolism
52. Lymphocyte activation gene 3 and coronary artery disease
    Diana Golden, Antonina Kolmakova, Sunitha R. Sura, Anthony T. Vella, Ani W Manichaikul, Xin‐Qun Wang, Suzette J. Bielinski, Kent D. Taylor, Yii‐Der Ida Chen, Stephen S. Rich et al. · 2016 · JCI Insight
53. Triglycerides, Atherosclerosis, and Cardiovascular Outcome Studies: Focus on Omega-3 Fatty Acids
    Yehuda Handelsman, Michael David Shapiro · 2016 · Endocrine Practice
54. Markers of Atherosclerosis: Part 2 – Genetic and Imaging Markers
    Miha Tibaut, Martin Čaprnda, Peter Kubatka, Andreja Sinkovič, Vanda Valentová, Slavomíra Filipová, Katarína Gazdíková, Ľudovít Gašpar, Ioana Monica Mozos, Emmanuel Eroume A Egom et al. · 2018 · Heart Lung and Circulation
55. A systematic review of the present and future of non-alcoholic fatty liver disease
    Christiana Lucas, Georgia Lucas, Nicholas Lucas, Joanna Krzowska-Firych, Krzysztof Tomasiewicz · 2018 · Clinical and Experimental Hepatology
56. Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease
    William E. Boden, Michael G. Miller, Ruth McBride, Christopher Harvey, Michael C. Snabes, Jeffrey M. Schmidt, Mark E. McGovern, Jerome L. Fleg, Patrice M. Desvigne-Nickens, Todd J. Anderson et al. · 2020 · American Heart Journal
57. Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl
    Rana, Jamal S., Liu, Jennifer Y., Moffet, Howard H., Solomon, Matthew D., Go, Alan S., Jaffe, Marc G., Karter, Andrew J. · 2015 · The American Journal of Cardiology
58. Antisense Oligonucleotides Targeting Lipoprotein(a)
    Anne Langsted, Børge Grønne Nordestgaard · 2019 · Current Atherosclerosis Reports
59. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review
    Raviteja Reddy Guddeti, Shantanu Patil, Aiza Ahmed, Arindam Sharma, Ahmed Aboeata, Carl J. Lavie, Venkata Mahesh Alla · 2020 · Progress in Cardiovascular Diseases
60. The Role of High-Density Lipoprotein Cholesterol in 2022
    Cesare Riccardo Sirtori, Alberto Corsini, Massimiliano Ruscica · 2022 · Current Atherosclerosis Reports
61. Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment
    L. Masana, Núria Plana, Natàlia Andreychuk, Daiana Ibarretxe · 2023 · Pharmacological Research
62. Relationships Between Serum and Urine Phosphorus With All-Cause and Cardiovascular Mortality: The Osteoporotic Fractures in Men (MrOS) Study
    Julie R. Dominguez, Bryan R. Kestenbaum, Michel Chonchol, Geoffrey A. Block, Gail A. Laughlin, Cora Elizabeth Lewis, Ronit Katz, Elizabeth L. Barrett-Connor, Steve Cummings, ERIC S. ORWOLL et al. · 2012 · American Journal of Kidney Diseases
63. Effect of an l-Carnitine–Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial
    Mario Bonomini, Lorenzo Di Liberato, Goffredo Del Rosso, Antonio Stingone, Giancarlo Marinangeli, Agostino Consoli, Silvio Volmer Bertoli, Amedeo De Vecchi, Emanuele Bosi, Roberto Russo et al. · 2013 · American Journal of Kidney Diseases
64. Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications
    Barak Zafrir, Mohit Jain · 2014 · Cardiovascular Drugs and Therapy
65. HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity
    Mark S. Borja, Kit Fai Ng, Angela D. Irwin, Jaekyoung Hong, Xing Wu, Daniel A. Isquith, Xue-Qiao Zhao, Bryan J. Prazen, Virginia L. Gildengorin, Michael N. Oda et al. · 2015 · Journal of Lipid Research
66. Time to ditch HDL-C as a measure of HDL function?
    Graziella E. Ronsein, Jay W. Heinecke · 2017 · Current Opinion in Lipidology
67. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid
    Samuel C. R. Sherratt, Richard Preston Mason · 2018 · Biochemical and Biophysical Research Communications
68. The art of cardiovascular risk assessment
    Jay Khambhati, Marc Allard‐Ratick, Devinder Singh Dhindsa, Suegene K. Lee, John Li Chen, Pratik B. Sandesara, Wesley T. O’Neal, Arshed Ali Quyyumi, Nathan D. Wong, Roger Scott Blumenthal et al. · 2018 · Clinical Cardiology
69. Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective
    Parhofer, Klaus G. · 2015 · Atherosclerosis Supplements
70. HDL: Quality or quantity?
    Carlos G. Santos‐Gallego · 2015 · Atherosclerosis
71. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine
    Esther Reijnders, Arnoud van der Laarse, J. Wouter Jukema, Christa M. Cobbaert · 2023 · Frontiers in Cardiovascular Medicine
72. High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease
    Tetsuya Ishikawa, Makoto Ayaori, Harumi Uto‐Kondo, Takatomo Nakajima, Makoto Mutoh, Katsunori Ikewaki · 2015 · Atherosclerosis
73. Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis
    Berglund, Lars, Brunzell, John D., Goldberg, Anne C., Goldberg, Ira J., Stalenhoef, Anton · 2014 · Best Practice & Research Clinical Endocrinology & Metabolism
74. From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport
    Alberto Dávalos, Carlos F Fernandez-Hernando · 2013 · Pharmacological Research
75. High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management
    Hong Y. Choi, Anouar Hafiane, Adel Giaid Schwertani, Jacques J. Genest · 2016 · Canadian Journal of Cardiology
76. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
    Marie-Jeanne Bertrand, Jean‐Claude Tardif · 2016 · Expert Opinion on Emerging Drugs
77. Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management
    Dhrubajyoti Bandyopadhyay, Arshna Qureshi, Sudeshna Ghosh, Kumar Ashish, Lyndsey R. Heise, Adrija Hajra, Raktim Kumar Ghosh · 2018 · Journal of Lipids
78. High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk
    Bela F. Asztalos, Katalin V. Horvath, Ernst J. Schaefer · 2018 · Arteriosclerosis Thrombosis and Vascular Biology
79. Lipid and metabolic syndrome traits in coronary artery disease: a Mendelian randomization study
    David G. Thomas, Ying Wei, Alan R. Tall · 2020 · Journal of Lipid Research
80. Apolipoprotein M
    Kun Ren, Zhen‐Li Tang, Yue Jiang, Yanmei Tan, Guang‐Hui Yi · 2015 · Clinica Chimica Acta
81. Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer’s Disease: A Narrative Review
    Zimetti, Francesca, Adorni, Maria Pia, Marsillach, Judit, Marchi, Cinzia, Trentini, Alessandro, Valacchi, Giuseppe, Cervellati, Carlo · 2021 · Oxidative Medicine and Cellular Longevity
82. Increased maternal and fetal cholesterol efflux capacity and placental CYP27A1 expression in preeclampsia
    Hiten D. Mistry, Lesia O. Kurlak, Yosef T. Mansour, Line Zurkinden, Markus Georg Mohaupt, Geneviève Escher · 2017 · Journal of Lipid Research
83. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes
    Michela Triolo, Wijtske Annema, Jan Freark de Boer, Uwe J.F. Tietge, Robin P. F. Dullaart · 2013 · European Journal of Clinical Investigation
84. Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease
    Beatriz Talayero, Liyun Wang, Jeremy D. Furtado, Vincent J. Carey, George A. Bray, Frank M. Sacks · 2014 · Journal of Lipid Research
85. A Comparative Overview of Prescription Omega-3 Fatty Acid Products.
    Matthew K. Ito · 2015 · PubMed Central
86. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial
    Nimisha Jain, Shobhit Bhansali, Anura V. Kurpad, Meredith A. Hawkins, Akhilesh Dayanand Sharma, Sandeep Kaur, Ashu Rastogi, Anil Kumar Bhansali · 2019 · Scientific Reports
87. Hypertriglyceridemia: new approaches in management and treatment
    Anna T Wolska, Zhihong Yang, Alan Thomas Remaley · 2020 · Current Opinion in Lipidology
88. Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin
    Julien Hanson, Andreas Gille, Stefan Offermanns · 2012 · Pharmacology & Therapeutics
89. Advances in the Understanding of Plaque Composition and Treatment Options
    Matthew Ian Tomey, Jagat Narula, Jason Ciril Kovacic · 2014 · Journal of the American College of Cardiology
90. Dyslipidemia management update
    Yingzi Chang, Jacques Robidoux · 2017 · Current Opinion in Pharmacology
91. Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis
    Ou Zhong, Jinyuan Wang, Yongpeng Tan, Xiaocan Lei, Zhi‐Han Tang · 2022 · Nutrition & Metabolism
92. Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication
    Anton P. van de Woestijne, Yolanda van der Graaf, Anho H Liem, Maarten Jan Cramer, Jan Westerink, Frank L.J. Visseren · 2013 · Journal of the American College of Cardiology
93. Progesterone Therapy, Endothelial Function and Cardiovascular Risk Factors: A 3-Month Randomized, Placebo-Controlled Trial in Healthy Early Postmenopausal Women
    Jerilynn C. Prior, Thomas G. Elliott, Eric G. Norman, Vesna Stajic, Christine L. Hitchcock · 2014 · PLoS ONE
94. Complementary phenol‐enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, double‐blind, crossover, controlled trial. The VOHF study
    Marta Farràs, Olga Castañer, Sandra Martín‐Peláez, Álvaro Hernáez, Helmut Schröder, Isaac Subirana, Daniel Muñoz‐Aguayo, Sònia Gaixas, Rafael de la Torre, Magı́ Farré et al. · 2015 · Molecular Nutrition & Food Research
95. Alirocumab for Hyperlipidemia: Physiology of PCSK9 inhibition, Pharmacodynamics and Phase I and Ii Clinical Trial Results of a PCSK9 Monoclonal Antibody
    Eli M. Roth, Philip M. Diller · 2014 · Future Cardiology
96. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options
    Adam N. Berman, Ron Blankstein · 2019 · Current Cardiology Reports
97. Differential tissue and ligand-dependent signaling of GPR109A receptor: Implications for anti-atherosclerotic therapeutic potential
    Ibragim Gaidarov, Xiaohua Chen, Todd L. Anthony, Dominique Maciejewski-Lenoir, Chen W. Liaw, David J. Unett · 2013 · Cellular Signalling
98. Niacin and HDL Cholesterol — Time to Face Facts
    Donald M. Lloyd‐Jones · 2014 · New England Journal of Medicine
99. Niacin: another look at an underutilized lipid-lowering medication
    Julia C. Creider, Robert Alexander Hegele, TISHA R. JOY · 2012 · Nature Reviews Endocrinology
100. HDL re-examined
     G. Kees Hovingh, Daniel James Rader, Robert Alexander Hegele · 2015 · Current Opinion in Lipidology